Shopping Cart
Remove All
Your shopping cart is currently empty
CRT0273750 regulates plasma LPA levels and is suitable for in vivo studies. CRT0273750 is an autotaxin (ATX) inhibitor with IC50 of 0.014 μM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | In Stock | In Stock | |
| 5 mg | $71 | In Stock | In Stock | |
| 10 mg | $116 | In Stock | In Stock | |
| 25 mg | $238 | In Stock | In Stock | |
| 50 mg | $357 | In Stock | In Stock | |
| 100 mg | $535 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $77 | In Stock | In Stock |
| Description | CRT0273750 regulates plasma LPA levels and is suitable for in vivo studies. CRT0273750 is an autotaxin (ATX) inhibitor with IC50 of 0.014 μM. |
| Targets&IC50 | ATX:0.014 μM |
| In vitro | CRT0273750 is also shown to inhibit the migration of 4T1 cells with an EC50 of 0.025μM[1]. CRT0273750 shows high potency in both the biochemical (IC50 = 0.01 μM) and plasma choline release assay(IC50 = 0.014 μM)[1]. |
| In vivo | CRT0273750 treatment shows the Cmax, AUC and t1/2 values of 3.8 μM, 3.2 μM.h and 1.4 h, respectively and shows a proportional increase[1].CRT0273750 has a moderate blood clearance, with value of 41 mL/min/kg[1]. |
| Synonyms | CRT-0273750, CRT 0273750 |
| Molecular Weight | 502.92 |
| Formula | C25H22ClF3N4O2 |
| Cas No. | 1979939-16-6 |
| Smiles | C[C@H](NC(=O)CCc1nc2cccnc2n1Cc1ccc(OC(F)(F)F)cc1)c1ccc(Cl)cc1 |
| Relative Density. | 1.35 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 200 mg/mL (397.68 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (6.56 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.